273 related articles for article (PubMed ID: 21742972)
1. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.
White AL; Chan HT; Roghanian A; French RR; Mockridge CI; Tutt AL; Dixon SV; Ajona D; Verbeek JS; Al-Shamkhani A; Cragg MS; Beers SA; Glennie MJ
J Immunol; 2011 Aug; 187(4):1754-63. PubMed ID: 21742972
[TBL] [Abstract][Full Text] [Related]
2. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
White AL; Chan HT; French RR; Beers SA; Cragg MS; Johnson PW; Glennie MJ
Cancer Immunol Immunother; 2013 May; 62(5):941-8. PubMed ID: 23543215
[TBL] [Abstract][Full Text] [Related]
3. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
4. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Richman LP; Vonderheide RH
Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
Li F; Ravetch JV
Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
[TBL] [Abstract][Full Text] [Related]
6. Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.
Vaughan AT; Chan CH; Klein C; Glennie MJ; Beers SA; Cragg MS
J Biol Chem; 2015 Feb; 290(9):5424-37. PubMed ID: 25568316
[TBL] [Abstract][Full Text] [Related]
7. Anti-FcγRIIB mAb suppresses murine IgG-dependent anaphylaxis by Fc domain targeting of FcγRIII.
Clay CD; Strait RT; Mahler A; Khodoun MV; Finkelman FD
J Allergy Clin Immunol; 2018 Apr; 141(4):1373-1381.e5. PubMed ID: 28624610
[TBL] [Abstract][Full Text] [Related]
8. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
Liu X; Zhao Y; Shi H; Zhang Y; Yin X; Liu M; Zhang H; He Y; Lu B; Jin T; Li F
Nat Commun; 2019 Sep; 10(1):4206. PubMed ID: 31562320
[TBL] [Abstract][Full Text] [Related]
9. Galactosylation of IgG1 modulates FcγRIIB-mediated inhibition of murine autoimmune hemolytic anemia.
Yamada K; Ito K; Furukawa J; Nakata J; Alvarez M; Verbeek JS; Shinohara Y; Izui S
J Autoimmun; 2013 Dec; 47():104-10. PubMed ID: 24055197
[TBL] [Abstract][Full Text] [Related]
10. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
Wilson NS; Yang B; Yang A; Loeser S; Marsters S; Lawrence D; Li Y; Pitti R; Totpal K; Yee S; Ross S; Vernes JM; Lu Y; Adams C; Offringa R; Kelley B; Hymowitz S; Daniel D; Meng G; Ashkenazi A
Cancer Cell; 2011 Jan; 19(1):101-13. PubMed ID: 21251615
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Dahan R; Barnhart BC; Li F; Yamniuk AP; Korman AJ; Ravetch JV
Cancer Cell; 2016 Jun; 29(6):820-831. PubMed ID: 27265505
[TBL] [Abstract][Full Text] [Related]
12. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.
Horton HM; Bernett MJ; Peipp M; Pong E; Karki S; Chu SY; Richards JO; Chen H; Repp R; Desjarlais JR; Zhukovsky EA
Blood; 2010 Oct; 116(16):3004-12. PubMed ID: 20616215
[TBL] [Abstract][Full Text] [Related]
13. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.
Williams EL; Tutt AL; Beers SA; French RR; Chan CH; Cox KL; Roghanian A; Penfold CA; Butts CL; Boross P; Verbeek JS; Cragg MS; Glennie MJ
J Immunol; 2013 Oct; 191(8):4130-40. PubMed ID: 24026082
[TBL] [Abstract][Full Text] [Related]
15. Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake.
Yada A; Ebihara S; Matsumura K; Endo S; Maeda T; Nakamura A; Akiyama K; Aiba S; Takai T
Cell Immunol; 2003 Sep; 225(1):21-32. PubMed ID: 14643301
[TBL] [Abstract][Full Text] [Related]
16. Rapid desensitization of mice with anti-FcγRIIb/FcγRIII mAb safely prevents IgG-mediated anaphylaxis.
Khodoun MV; Kucuk ZY; Strait RT; Krishnamurthy D; Janek K; Clay CD; Morris SC; Finkelman FD
J Allergy Clin Immunol; 2013 Dec; 132(6):1375-87. PubMed ID: 24139828
[TBL] [Abstract][Full Text] [Related]
17. Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.
Chenoweth AM; Esparon S; Wines BD; Schuurman J; Labrijn AF; Hogarth PM
Immunol Cell Biol; 2023 Aug; 101(7):657-662. PubMed ID: 36997299
[TBL] [Abstract][Full Text] [Related]
18. Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcgammaRIIB.
Nandakumar KS; Andrén M; Martinsson P; Bajtner E; Hellström S; Holmdahl R; Kleinau S
Eur J Immunol; 2003 Aug; 33(8):2269-77. PubMed ID: 12884302
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.
Iwayanagi Y; Igawa T; Maeda A; Haraya K; Wada NA; Shibahara N; Ohmine K; Nambu T; Nakamura G; Mimoto F; Katada H; Ito S; Tachibana T; Jishage K; Hattori K
J Immunol; 2015 Oct; 195(7):3198-205. PubMed ID: 26320252
[TBL] [Abstract][Full Text] [Related]
20. Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies.
Kim D; Huey D; Oglesbee M; Niewiesk S
Blood; 2011 Jun; 117(23):6143-51. PubMed ID: 21357766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
